Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML

NCT02461537 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

281

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: HAM
DRUG: LDAC and/or Mitoxantrone

Sponsor

DKMS gemeinnützige GmbH